These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 10591243)
1. Managing dyslipidemia in older adults. Carlsson CM; Carnes M; McBride PE; Stein JH J Am Geriatr Soc; 1999 Dec; 47(12):1458-65. PubMed ID: 10591243 [TBL] [Abstract][Full Text] [Related]
2. Treatment of diabetic dyslipidemia. Garg A Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814 [TBL] [Abstract][Full Text] [Related]
3. Management of blood lipid abnormalities in coronary heart disease patients. Kuo PT Clin Cardiol; 1989 Oct; 12(10):553-60. PubMed ID: 2680196 [TBL] [Abstract][Full Text] [Related]
4. Management of dyslipidemia in adults with diabetes. Haffner SM Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988 [TBL] [Abstract][Full Text] [Related]
5. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Borgia MC; Medici F Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of coronary heart disease prevention strategies in adults. Brown AD; Garber AM Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193 [TBL] [Abstract][Full Text] [Related]
8. Dyslipidemias and the secondary prevention of coronary heart disease. Rosenson RS; Frauenheim WA; Tangney CC Dis Mon; 1994 Aug; 40(8):369-464. PubMed ID: 8050340 [TBL] [Abstract][Full Text] [Related]
9. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. Ansell BJ; Watson KE; Fogelman AM JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388 [TBL] [Abstract][Full Text] [Related]
10. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
12. Lipoprotein disorders in women: which women are the best candidates for hormone replacement therapy? Plushner SL Ann Pharmacother; 1997 Jan; 31(1):98-107. PubMed ID: 8997474 [TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. Dujovne CA; Moriarty PM Clin Ther; 1996; 18(3):392-410; discussion 391. PubMed ID: 8829016 [TBL] [Abstract][Full Text] [Related]
14. Treatment of hyperlipidemia in women. Walsh JM; Grady D JAMA; 1995 Oct; 274(14):1152-8. PubMed ID: 7563487 [TBL] [Abstract][Full Text] [Related]
15. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
16. The triglyceride-high-density lipoprotein axis: an important target of therapy? Szapary PO; Rader DJ Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990 [TBL] [Abstract][Full Text] [Related]
17. Management of hypercholesterolaemia in postmenopausal women. Davidson MH; Maki KC; Karp SK; Ingram KA Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776 [TBL] [Abstract][Full Text] [Related]